Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus - Test2 - elhamkhani - TriplyDB

Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus

Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus

http://www.wikidata.org/entity/Q28066209

about

Lung ischemia reperfusion injury: the therapeutic role of dipeptidyl peptidase 4 inhibition.Gemigliptin: Newer Promising Gliptin for Type 2 Diabetes Mellitus.Protective Effects of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, against Cisplatin-Induced Nephrotoxicity in Mice.Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study.Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, pl Effects of gemigliptin, a dipeptidyl peptidase-4 inhibitor, on lipid metabolism and endotoxemia after a high-fat meal in patients with type 2 diabetes.Comparative Cardiovascular Risks of Dipeptidyl Peptidase-4 Inhibitors: Analyses of Real-world Data in Korea.

P2860

Q39277184-E152AD11-6E12-4C42-AC9F-6DF36B066667 Q47137374-F1E64D85-A902-4B81-B0B5-1F478A919729 Q47215463-51DCEE05-84A7-4197-A25D-E5AC9B058DFA Q48108721-24A85A1B-9D58-4291-A60E-1CD468F0B109 Q51233383-52CE578E-D024-44C2-B027-AB1B1633F33C Q51276064-BDAC27E3-3AF8-4401-9F45-FA635A2187FE Q54993721-440BB2A4-5950-477A-B14D-EBAFA1535231

P2860

Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus

http://www.wikidata.org/entity/Q28066209

description

2016 nî lūn-bûn

@nan

2016 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus

@ast

Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus

@en

Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus

@nl

type

label

Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus

@ast

Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus

@en

Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus

@nl

prefLabel

Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus

@ast

Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus

@en

Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus

@nl

P1433

Q28066209-6DC59DEF-46F8-48B6-BF23-DFD97801EDB2

P1476

Q28066209-6B3ECDB5-6CF6-4C36-A55B-0CAE5D1C90CC

P2093

Q28066209-8FB03D08-5B11-4C22-86D0-44C59F1137F9

Q28066209-A5A9DCC5-E35F-4563-84FD-A9F7F8BB230A

Q28066209-B7E8188C-02EC-47E7-BDA3-0B029A5365C3

P2860

Q28066209-0386B38E-26F9-4742-AEF2-530157C080F1

Q28066209-05849A43-2645-458B-A7F9-753B0800D02E

Q28066209-073E65CF-B307-4925-BD88-8C2CE5DDAD4D

Q28066209-0BEDD002-62AE-43AC-84A2-EF76DE4B99C3

Q28066209-0C9B94B1-11A2-4FA1-B178-9194499F1A5A

Q28066209-0D034AD7-3338-437B-8E9F-BA4F5D99E9AC

Q28066209-129C5C98-9D02-4F4A-992F-DC721792055B

Q28066209-1B2060BA-DA26-420B-9743-E1CFCF142834

Q28066209-2E586C30-9CF4-4A9A-9C68-756F127A9C5C

Q28066209-34A90EB9-5B9C-4246-B376-54E588AADB73

P304

Q28066209-5F8ED29A-AF23-4C63-B171-9E7A1F1C7E33

P31

Q28066209-49EA862F-97DD-4664-B438-B4840243039B

P3181

Q28066209-CFD5CB35-AA8D-4AE4-9F1D-406D70723819

P356

Q28066209-BEE5F709-0DCD-47B6-A736-7B45F2E4F839

P407

Q28066209-E7B1EA0C-BDB7-4D9E-A25C-04072797DCF8

P433

Q28066209-B85994F4-9D2D-48DE-9D1E-C0B145D2823E

P478

Q28066209-160CCAB4-D21D-4A4A-A141-372BF5E67463

P50

Q28066209-D262C2EA-DC92-41E0-BA4F-1CD9B28327D8

P577

Q28066209-D64F8AAA-CB91-46EA-869B-41F0BA31CD3F

P698

Q28066209-D79D2C33-660D-402D-AD49-E22207321968

P921

Q28066209-F1E4F34D-DC68-4784-91EE-9CC7A9168900

P932

Q28066209-3DA3B20C-7A38-446E-BCAB-917CE1E675C6

P3181

P356

DMJ.2016.40.5.339

P1433

Diabetes & metabolism journal

P1476

Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus

@en

P2093

Jung-Hwa Yoo

http://www.w3.org/2001/XMLSchema#string

Sung-Ho Kim

http://www.w3.org/2001/XMLSchema#string

Woo Je Lee

http://www.w3.org/2001/XMLSchema#string

P2860

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers

A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site

Dipeptidyl peptidase IV inhibitor protects against renal interstitial fibrosis in a mouse model of ureteral obstruction

Standards of medical care in diabetes--2014

Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system

A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes.

Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase IV inhibitor LC15-0444 and pioglitazone in healthy volunteers.

Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo.

Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea

P304

339-353

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3566293

http://www.w3.org/2001/XMLSchema#string

P356

10.4093/DMJ.2016.40.5.339

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

40

http://www.w3.org/2001/XMLSchema#string

P50

Cheol-Young Park

P577

2016-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27766241

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

5069390

http://www.w3.org/2001/XMLSchema#string